Alobaedi Omar H, Talib Wamidh H, Basheti Iman A
Department of Clinical Pharmacy & Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.
Department of Clinical Pharmacy & Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.
Asian Pac J Trop Med. 2017 Apr;10(4):400-408. doi: 10.1016/j.apjtm.2017.03.026. Epub 2017 Apr 7.
To test the anticancer potential activity of the combination of thymoquinone (TQ) and resveratrol (RES) against breast cancer in mice.
The antiproliferative activity of TQ, RES and their combination was assessed against three breast cancer cell lines and one normal cells using MTT assay. The combination index was calculated using isobolographic method. Balb/C mice were inoculated with EMT6/P cells and in vivo antitumor activity was evaluated.
The combination therapy also caused significant decrease in tumor size with a percentage cure of 60%. The combination therapy induced geographic necrosis, enhanced apoptosis, and decreased VEGF expression. Serum levels of IFN-γ were elevated in mice treated with combination therapy with no liver or kidney toxicity.
The combination of TQ and RES against breast cancer in mice can work synergistically. The anticancer effect of this combination is mediated by apoptosis induction, angiogenesis inhibition and immune modulation.
测试胸腺醌(TQ)与白藜芦醇(RES)联合用药对小鼠乳腺癌的潜在抗癌活性。
采用MTT法评估TQ、RES及其联合用药对三种乳腺癌细胞系和一种正常细胞的抗增殖活性。使用等效线法计算联合指数。将EMT6/P细胞接种到Balb/C小鼠体内,评估体内抗肿瘤活性。
联合治疗也使肿瘤大小显著减小,治愈率达60%。联合治疗诱导了地图状坏死,增强了细胞凋亡,并降低了VEGF表达。联合治疗的小鼠血清IFN-γ水平升高,且无肝肾毒性。
TQ与RES联合用药对小鼠乳腺癌具有协同作用。这种联合用药的抗癌作用是通过诱导细胞凋亡、抑制血管生成和免疫调节介导的。